Literature DB >> 9278461

Proteolytic cleavage of the mdm2 oncoprotein during apoptosis.

L Chen1, V Marechal, J Moreau, A J Levine, J Chen.   

Abstract

The mdm2 oncogene encodes a 90-kDa protein that can bind to the p53 tumor suppressor protein and negatively regulate its functions in transcription, cell cycle arrest, and apoptosis. The mdm2 gene is frequently amplified in human sarcomas, which may be responsible for the malignant transformations. We present evidence that the mdm2 oncoprotein is cleaved by an interleukin 1beta-converting enzyme-like protease (caspase) during p53-mediated apoptosis. The protease that cleaves mdm2 has a specificity similar to that of CPP32 (caspase-3), and recombinant caspase-3 is able to cleave mdm2 in vitro. The protease cleavage site has been mapped to between residue 361 and 362 of human mdm2. The proteolytic cleavage removes the COOH-terminal RING finger domain of mdm2, resulting in the loss of RNA binding activity. The p53 binding and inhibition functions of mdm2 are not affected by the cleavage. The cleavage site sequence of mdm2 is evolutionarily conserved, suggesting that regulation by caspase cleavage during apoptosis is an important feature of mdm2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278461     DOI: 10.1074/jbc.272.36.22966

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

Review 2.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

3.  Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.

Authors:  O Nyormoi; Z Wang; D Doan; M Ruiz; D McConkey; M Bar-Eli
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

4.  Development and characterization of 5 canine B-cell lymphoma cell lines.

Authors:  Allison L Zwingenberger; William Vernau; Changying Shi; Wensheng Yan; Xinbin Chen; Ira K Gordon; Michael S Kent
Journal:  Leuk Res       Date:  2011-12-01       Impact factor: 3.156

5.  ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.

Authors:  Qian Cheng; Lihong Chen; Zhenyu Li; William S Lane; Jiandong Chen
Journal:  EMBO J       Date:  2009-12-16       Impact factor: 11.598

Review 6.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

7.  Actin cleavage in various tumor cells is not a critical requirement for executing apoptosis.

Authors:  R L Rice; D G Tang; J D Taylor
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

8.  XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Authors:  Yan Cheng; Michael P Holloway; Kevin Nguyen; Dilara McCauley; Yosef Landesman; Michael G Kauffman; Sharon Shacham; Rachel A Altura
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

9.  Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration.

Authors:  Caroline Rouaux; Natasa Jokic; Corinne Mbebi; Stephanie Boutillier; Jean-Philippe Loeffler; Anne-Laurence Boutillier
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

10.  MDM2 promotes ubiquitination and degradation of MDMX.

Authors:  Yu Pan; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.